Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H14N2O4 |
Molecular Weight | 238.2403 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1ccc(cc1)C(COC(=N)O)COC(=N)O
InChI
InChIKey=WKGXYQFOCVYPAC-UHFFFAOYSA-N
InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)
DescriptionSources: http://www.drugbank.ca/drugs/DB00949Curator's Comment:: Description was created based on several sources, including
https://www.drugs.com/cdi/felbamate.html and https://www.ncbi.nlm.nih.gov/pubmed/8383742
Sources: http://www.drugbank.ca/drugs/DB00949
Curator's Comment:: Description was created based on several sources, including
https://www.drugs.com/cdi/felbamate.html and https://www.ncbi.nlm.nih.gov/pubmed/8383742
Felbamate is an antiepileptic indicated as monotherapy or as an adjunct to other anticonvulsants for the treatment of partial seizures resulting from epilepsy. Receptor-binding studies in vitro indicate that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding, and is devoid of activity at the MK-801 receptor binding site of the NMDA receptor-ionophore complex. However, felbamate does interact as an antagonist at the strychnine-insensitive glycine recognition site of the NMDA receptor-ionophore complex. The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. In vitro receptor binding studies suggest that felbamate may be an antagonist at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate (NMDA) receptor-ionophore complex. Antagonism of the NMDA receptor glycine binding site may block the effects of the excitatory amino acids and suppress seizure activity. Animal studies indicate that felbamate may increase the seizure threshold and may decrease seizure spread. It is also indicated that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding. Felbamate should be used only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. Felbatol is the brand name used in the United States for felbamate.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18311896 |
|||
Target ID: CHEMBL1904 Sources: http://www.drugbank.ca/drugs/DB00949 |
0.52 mM [IC50] | ||
Target ID: CHEMBL3038504 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10215667 |
2.02 mM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FELBATOL Approved UseNot indicated as a first line antiepileptic treatment (see WARNINGS). Recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, Felbamate tablets can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children. Launch Date7.4381761E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.2 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9241102 |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
FELBAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
49 μg/mL |
45 mg/kg 1 times / day steady-state, oral dose: 45 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FELBAMATE plasma | Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
526 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9241102 |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
FELBAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
19.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9241102 |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
FELBAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
20 h |
45 mg/kg 1 times / day steady-state, oral dose: 45 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FELBAMATE plasma | Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1200 mg 3 times / day steady, oral Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: steady Dose: 1200 mg, 3 times / day Sources: |
unhealthy, 30 years (range: 18-45 years) n = 5 Health Status: unhealthy Condition: epilepsy Age Group: 30 years (range: 18-45 years) Sex: F Population Size: 5 Sources: |
Other AEs: Headache, Nausea... Other AEs: Headache (1 patient) Sources: Nausea (5 patients) Anorexia (3 patients) Dyspepsia (1 patient) Insomnia (1 patient) |
1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Other AEs: Fatigue, Weight decrease... Other AEs: Fatigue (6.9%) Sources: Weight decrease (3.4%) Face edema (3.4%) Insomnia (8.6%) Headache (6.9%) Anxiety (5.2%) Acne (3.4%) Rash (3.4%) Dyspepsia (8.6%) Vomiting (8.6%) Constipation (6.9%) Diarrhea (5.2%) SGPT increased (5.2%) Hypophosphatemia (3.4%) Upper respiratory tract infection (8.6%) Rhinitis (6.9%) Diplopia (3.4%) Otitis media (3.4%) Bleeding intermenstrual (3.4%) Urinary tract infection (3.4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dyspepsia | 1 patient | 1200 mg 3 times / day steady, oral Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: steady Dose: 1200 mg, 3 times / day Sources: |
unhealthy, 30 years (range: 18-45 years) n = 5 Health Status: unhealthy Condition: epilepsy Age Group: 30 years (range: 18-45 years) Sex: F Population Size: 5 Sources: |
Headache | 1 patient | 1200 mg 3 times / day steady, oral Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: steady Dose: 1200 mg, 3 times / day Sources: |
unhealthy, 30 years (range: 18-45 years) n = 5 Health Status: unhealthy Condition: epilepsy Age Group: 30 years (range: 18-45 years) Sex: F Population Size: 5 Sources: |
Insomnia | 1 patient | 1200 mg 3 times / day steady, oral Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: steady Dose: 1200 mg, 3 times / day Sources: |
unhealthy, 30 years (range: 18-45 years) n = 5 Health Status: unhealthy Condition: epilepsy Age Group: 30 years (range: 18-45 years) Sex: F Population Size: 5 Sources: |
Anorexia | 3 patients | 1200 mg 3 times / day steady, oral Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: steady Dose: 1200 mg, 3 times / day Sources: |
unhealthy, 30 years (range: 18-45 years) n = 5 Health Status: unhealthy Condition: epilepsy Age Group: 30 years (range: 18-45 years) Sex: F Population Size: 5 Sources: |
Nausea | 5 patients | 1200 mg 3 times / day steady, oral Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: steady Dose: 1200 mg, 3 times / day Sources: |
unhealthy, 30 years (range: 18-45 years) n = 5 Health Status: unhealthy Condition: epilepsy Age Group: 30 years (range: 18-45 years) Sex: F Population Size: 5 Sources: |
Acne | 3.4% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Bleeding intermenstrual | 3.4% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Diplopia | 3.4% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Face edema | 3.4% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Hypophosphatemia | 3.4% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Otitis media | 3.4% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Rash | 3.4% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Urinary tract infection | 3.4% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Weight decrease | 3.4% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Anxiety | 5.2% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Diarrhea | 5.2% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
SGPT increased | 5.2% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Constipation | 6.9% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Fatigue | 6.9% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Headache | 6.9% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Rhinitis | 6.9% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Dyspepsia | 8.6% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Insomnia | 8.6% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Upper respiratory tract infection | 8.6% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Vomiting | 8.6% | 1200 mg 3 times / day multiple, oral Recommended Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: |
unhealthy, adult n = 58 Health Status: unhealthy Condition: epilepsy Age Group: adult Population Size: 58 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/9314612/ Page: 7.0 |
likely | yes (co-administration study) Comment: Felbamate reduced mean gestodene AUCO-24h by -42% compared with baseline, while a minor decrease (-13%), which was not assessed to be clinically relevant, was observed in ethinyl estradiol AUCO-24h Sources: https://pubmed.ncbi.nlm.nih.gov/9314612/ Page: 7.0 |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/9314612/ Page: 3.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/9314612/ Page: 3,6 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/9314612/ Page: 4.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/9314612/ Page: 4.0 |
slight | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/9314612/ Page: 2.0 |
yes [Inhibition 1 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/9314612/ Page: 6.0 |
yes [Ki 225 uM] | weak (co-administration study) Comment: AUCtao of phenytoin (substrate) increased by 30% when given Felbamate (1200 mg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/9314612/ Page: 6.0 |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/9314612/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12113905/ Page: 4.0 |
likely | |||
yes | ||||
yes | weak (co-administration study) Comment: Carbamazepine and phenytoin increased felbamate apparent clearance by 32 to 38% relative to monotherapy Sources: https://pubmed.ncbi.nlm.nih.gov/9314612/ |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. | 1992 Mar |
|
Felbamate, a novel antiepileptic agent, does not affect cognition in rodents. | 1994 Jun |
|
Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain. | 1999 Apr |
|
Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action. | 1999 May |
|
Felbamate in experimental model of status epilepticus. | 2000 Feb |
|
A self-complementary, self-assembling microsphere system: application for intravenous delivery of the antiepileptic and neuroprotectant compound felbamate. | 2000 Jul |
|
[New antiepileptic drugs in childhood epilepsies: indications and limits]. | 2001 |
|
Second generation anticonvulsant medications: their use in children. | 2001 Apr |
|
Newer antiepileptic drugs: advantages and disadvantages. | 2001 Aug |
|
[Antiepileptic drugs and neuropathic pain]. | 2001 Feb 16-28 |
|
The role of new antiepileptic drugs. | 2001 Jul |
|
Monotherapy trials: presurgical studies. | 2001 May |
|
The long-term use of felbamate in children with severe refractory epilepsy. | 2001 Nov |
|
The NMDA receptor complex: a promising target for novel antiepileptic strategies. | 2001 Sep |
|
Anticonvulsants: aspects of their mechanisms of action. | 2002 |
|
New antiepileptic drugs: review on drug interactions. | 2002 Feb |
|
Marketed new antiepileptic drugs: are they better than old-generation agents? | 2002 Feb |
|
Interaction between human serum albumin and the felbamate metabolites 4-Hydroxy-5-phenyl-[1,3]oxazinan-2-one and 2-phenylpropenal. | 2002 Jun |
|
Polytherapy in epilepsy: the experimental evidence. | 2002 Nov |
|
Drug treatment of epilepsy in elderly people: focus on valproic Acid. | 2003 |
|
Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats. | 2003 Dec |
|
Influence of some convulsant agents on the protective activity of a novel antiepileptic drug, felbamate, against maximal electroshock in mice. | 2003 Jul-Aug |
|
Therapeutic drug monitoring of the newer antiepileptic drugs. | 2003 Jun |
|
Synergistic interaction between felbamate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice. | 2003 Mar 28 |
|
Investigating the role of 2-phenylpropenal in felbamate-induced idiosyncratic drug reactions. | 2004 Dec |
|
Behavioural effects of the newer antiepileptic drugs: an update. | 2004 Jan |
|
New antiepileptic agents. | 2004 Jan-Feb |
|
Influence of felbamate on selected central effects of ethanol in experimental animals. | 2004 May-Jun |
|
Is there any future for felbamate treatment? | 2004 May-Jun |
|
Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. | 2004 Oct 9 |
|
Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. | 2005 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/cdi/felbamate.html
Adjunctive therapy: 1200 mg/day in 3-4 divided doses. The daily dose can be increased in 1200 mg increments each week as tolerated to response. Maximum daily dose: 3600 mg.
Monotherapy: 1200 mg/day in 3-4 divided doses. Increase the daily dose in 600 mg increments every two weeks as tolerated to response.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8613908
At concentrations of 30 to 100 nM, Felbamate produced a significant inhibition of high-voltage-activated Ca++ currents (-6/-15%). At saturating concentrations (1-3 uM), Felbamate-mediated inhibition averaged 44% in rat cortical and neostriatal neurons.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
401
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
||
|
NCI_THESAURUS |
C264
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
||
|
NDF-RT |
N0000008486
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
||
|
NDF-RT |
N0000175753
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
||
|
FDA ORPHAN DRUG |
33488
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
||
|
WHO-ATC |
N03AX10
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
||
|
WHO-VATC |
QN03AX10
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
24812
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | RxNorm | ||
|
C047360
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
C47530
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
25451-15-4
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
5473
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
SUB07526MIG
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
25451-15-4
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
7525
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
X72RBB02N8
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
FELBAMATE
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
DB00949
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
M5254
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | Merck Index | ||
|
Felbamate
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
3331
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
5686
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
1140
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
1269312
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | USP-RS | ||
|
247-001-4
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY | |||
|
CHEMBL1094
Created by
admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
|
PRIMARY |
ACTIVE MOIETY